ArticleCrohn's & colitis 3602026
Prevalence, timing and risk factors of extraintestinal manifestations in inflammatory bowel disease: a retrospective cohort study from a German tertiary referral center.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extraintestinal manifestations (EIMs) are a frequent and clinically significant feature of inflammatory bowel disease (IBD), contributing to morbidity and impaired quality of life. Objectives: To investigate the prevalence, spectrum, timing, and risk factors of EIMs in a large cohort of patients with IBD. Methods: In this retrospective cohort study, adult patients with ulcerative colitis (UC) or Crohn's disease (CD) followed at a German tertiary referral center were included. Electronic medical records were reviewed to identify specialist-confirmed EIMs, their timing relative to IBD diagnosis, and associated demographic and disease-related factors. Results: A total of 817 patients with IBD (527 CD, 290 UC) were included, with a median disease duration of 11 years (IQR 6-19). EIMs were identified in 227 patients (27.8%), with rheumatologic (17.4%) and cutaneous (8.9%) manifestations being the most frequent. Most patients had one EIM (70%), while 30% developed multiple manifestations. Female sex (OR 2.88; 95% CI 2.08-4.02, Conclusion: EIMs affect more than one quarter of patients with IBD and may precede or coincide with intestinal disease onset. Female sex and CD appear to be independent risk factors. These findings highlight the importance of early recognition and long-term surveillance of EIMs in patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.